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Abstract.  M cells of intestinal  epithelia overlying 
lymphoid follicles endocytose luminal  macromolecules 
and microorganisms and deliver them to underlying 
lymphoid tissue.  The effect of luminal  secretory IgA 
antibodies on adherence and transepithelial  transport 
of antigens and  microorganisms by M  cells is un- 
known.  We have studied the interaction of monoclonal 
IgA antibodies directed against specific enteric viruses, 
or the hapten trinitrophenyl  (TNP),  with M  cells.  To 
produce monospecific IgA antibodies against mouse 
mammary tumor virus (MMTV) and reovirus type  1, 
Peyer's patch cells from mucosally immunized  mice 
were fused with myeloma cells, generating  hybridomas 
that secreted virus-specific IgA antibodies in mono- 
meric and polymeric forms.  One of two anti-MMTV 
IgA antibodies specifically bound the viral surface gly- 
coprotein gp52, and 3 of 10 antireovirus IgA antibod- 
ies immunoprecipitated  sigma 3 and mu lc surface 
proteins.  35S-labeled IgA antibodies injected intrave- 
nously into rats were recovered in bile as higher too- 
lecular weight species, suggesting that secretory com- 
ponent had been added on passage through the liver. 
Radiolabeled or colloidal gold-conjugated mouse IgA 
was injected into mouse, rat,  and rabbit intestinal 
loops containing  Peyer's patches.  Light microscopic 
autoradiography and EM showed that all IgA antibod- 
ies (antivirus or anti-TNP) bound to M  cell luminal 
membranes and were transported  in vesicles across M 
cells. IgA-gold binding was inhibited by excess unla- 
beled IgA,  indicating  that binding was specific. IgG- 
gold also adhered to M  cells and excess unlabeled IgG 
inhibited IgA-gold binding;  thus binding was not 
isotype-specific. Immune complexes consisting of 
monoclonal anti-TNP IgA and TNP-ferritin adhered 
selectively to M  cell membranes,  while TNP-ferritin 
alone did not.  These results suggest that selective ad- 
herence of luminal  antibody to M  cells may facilitate 
delivery of virus-antibody complexes to mucosal l~m- 
phoid tissue, enhancing  subsequent secretory immune 
responses or facilitating viral invasion. 
T 
o enter cells and initiate replication,  viruses often ad- 
here to host cell plasma membranes and exploit cellu- 
lar endocytic activity (16). Certain enteric viruses that 
enter their hosts at intestinal  mucosal surfaces are internal- 
ized by epithelial cells, but do not infect the epithelium itself; 
rather,  they enter transepithelial  transport pathways to cross 
the intact epithelium  and spread  systemically  (20, 35). For 
example,  mouse mammary tumor virus (MMTV), ~ which 
is transmitted  in milk from mother to offspring, crosses the 
intestinal epithelium and subsequently replicates in the mam- 
mary gland (21). Reovirus type 1 adheres specifically  to M 
cells, specialized  epithelial  cells that overlie  mucosal lym- 
phoid follicles, and uses M cell transepithelial  transport ac- 
1.  Abbreviations  used in this paper:  FAE,  follicle-associated  epithelium; 
i.l.,  intraluminal; i.p.,  intraperitoneal; MLN,  mesenteric  lymph  node; 
MMTV, mouse mammary tumor virus; PP, Peyer's patch; slgA, secretory 
IgA; TNP,  trinitrophenyl. 
tivity to cross the epithelium  and spread to neural  and lym- 
phoid tissues (35, 48). 
M cells are specialized  for rapid transepithelial  transport 
of luminal macromolecules and microorganisms  to underly- 
ing lymphoid tissue (7, 25), a transport process that may lead 
to development of a specific secretory immune response (37, 
42). Thus, despite the fact that M cell transport activity pro- 
vides an entry point for some viruses, it may also be neces- 
sary  for subsequent production  of specific  secretory IgA 
(slgA)  against  these viruses.  Considerable evidence indi- 
cates that slgA (but not IgG) protects intestinal epithelial sur- 
faces and prevents enteric infection (1, 2, 4, 5, 24), but there 
is little information  on precisely how such protection is ac- 
complished.  It is generally  believed that  luminal  slgA in- 
hibits  absorption of viruses and  other microorganisms  by 
blocking the microbial surface molecules responsible for ep- 
ithelial  attachment  (44, 46), but this has not been directly 
demonstrated  in the intestine,  in part because the relevant 
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quantities. Nor is it known whether IgA can affect binding 
or transport of any macromolecule or microorganism by M 
cells. 
Our ultimate goal is to elucidate the mechanisms whereby 
slgA influences epithelial adherence and uptake of macro- 
molecules and microorganisms in the intestine by testing 
monospecific secretory antibodies in well-characterized sys- 
tems of viral infection and antigen transport. We have se- 
lected for study two viruses, reovirus type 1 and MMTV, 
both of which invade the intestinal mucosa by crossing an in- 
tact, undamaged intestinal epithelium (21, 35). A first step 
in these studies is the generation of monospecific antibodies 
of the IgA isotype, directed against viral surface components 
that may be important in intestinal attachment and invasion. 
As a model antigen, we selected the hapten trinitrophenyl 
(TNP),  since it is readily attached to ultrastructural tracer 
molecules,  and  monoclonal  anti-TNP  IgA  antibodies  are 
available. 
In this report, we describe the production and character- 
ization of monoclonal IgA antibodies directed against MMTV 
and reovirus type 1. Hybridomas were made by fusing my- 
eloma cells with Peyer's patch (PP) cells from mucosally im- 
munized mice, and the IgA antibodies obtained were charac- 
terized according to their protein binding specificity, degree 
of polymer formation, and ability to bind to liver polymeric 
immunoglobulin receptors. To test for possible interactions 
of antivirus and anti-TNP IgA antibodies with specific epi- 
thelial cell  surfaces,  metabolically labeled or gold-conju- 
gated IgA antibodies were injected into intestinal loops and 
visualized by autoradiography and electron microscopy. Our 
results indicate that luminal IgA binds selectively to M cell 
surfaces and thus may enhance delivery of antigens and mi- 
croorganisms across the follicle-associated  epithelium (FAE). 
Materials and Methods 
Animals 
Female BALB/c mice (Charles River Breeding Laboratories,  Inc.,  Wil- 
mington, MA) between the ages of 6 and 12 wk were used for feeder layer 
preparation  and  all  fusions.  Female  CD  rats  (Charles  River  Breeding 
Laboratories, Inc.) between the ages of 8 and  15 wk were used for liver 
transport experiments. Adult male or female BALB/c mice, female CD rats, 
and male or female New Zealand albino rabbits were used for injection of 
labeled antibodies into intestinal loops and for immunofluorescence  studies. 
Neonatal jejunum was obtained from ,',,12-d-old  CD rats. 
Cells and Cell Culture 
P3X63/Ag 8.653 mouse myeloma cells and hybridoma cells were grown in 
RPMI  1640  medium (Gibco Laboratories, Grand Island, NY) containing 
10% FBS, 2 mM glutamine, 10 mM Hepes, 24 mM NaHCO3,  1 mM so- 
dium pyruvate, 100 U/ml penicillin, and 100/zg/ml streptomycin (complete 
RPMI). L929 mouse fibroblastic cells were grown in Joklik's S-MEM (Ir- 
vine Scientific, Santa Ana, CA) containing 5% FBS, 3 mM glutamine, 100 
U/ml penicillin, and 100/zg/ml streptomycin, GR mouse mammary cells 
(obtained from Dr. H. Diggleman, Swiss Institute for Experimental Cancer 
Research, Epalinges, Switzerland) were grown in DME (Gibco Laborato- 
ries) containing 10% FBS, 2 mM glutamine, 10 mM NaHCO3,  100 U/ml 
penicillin, and  100 #g/ml streptomycin. 
Viruses 
MMTV  particles  were  purified  using  described methods  from  culture 
medium of GR cells, a mouse mammary cell line persistently infected with 
MMTV (27). Reovirus type 1 was grown in L929 cells and purified as previ- 
ously described (29). 
Immunization 
Immunization protocols are summarized in Table I. For MMTV immuniza- 
tion, BALB/c mice were immunized on day 0 with a suspension of MMTV- 
producing GR cells, injected either into the intestinal lumen (106 cells) or 
directly into the submucosal tissue of five to six PPs (1-2  x  105 cells/per 
patch). On days 14 and 21, mice were boosted with intraluminal (i.l.) or 
intraperitoneal (i.p.) injections of MMTV particles at a titer corresponding 
to 0.5 #g of gp52, the major viral surface glycoprotein. 
For reovirus immunization, two protocols were used, both involving ad- 
ministration of virus on days 0,  14, and 21, and fusion of PP cells on day 
24 (Table I). A virus suspension of 5  ×  l0  s particles was injected i.I. or 
i.p.;  for oral immunization, the same amount was given dropwise. 
Cell Isolation and Fusion 
For isolation of mouse PP mononuclear cells, the mucosa and submucosa 
of 8-10 PPs were removed and incubated in complete RMPI medium con- 
raining 0.1% collagenase for 1 h at 37°C. Tissues were ground between the 
ends of two sterile frosted-end microscope slides, and released cells were 
washed two times in complete RPMI. Approximately 2-3  ×  t07 viable PP 
mononuclear  leukocytes  were  recovered  from  one  mouse.  Spleen  and 
mesenteric lymph node (MLN) cells were isolated using the same tech- 
nique, except that the collagenase treatment was omitted. 
Myeloma cells and mouse mononuclear cells were washed twice with 
serum-free RPMI and fused in 37%  polyethylene glycol 4000 (E. Merck, 
Darmstadt, FRG) at a leukocyte to myeloma cell ratio of 5:1. After fusion, 
cells were diluted to  1 ×  106 celis/ml in complete RPMI and distributed 
into 96-well tissue culture plates that had been seeded 24 h earlier with 2  × 
104 irradiated (800  rads) mouse peritoneal exudate cells per well. Hybrid- 
omas were selected in hypoxanthine, aminopterin, and thymidine medium 
using standard methods. 
Production and Labeling of  Monoclonai Antibodies 
Hybridoma wells were screened for specific antibody production by ELISA. 
Wells were coated overnight at 4°C with 0,1 ml of MMTV at ,'~0.01/xg gp52 
protein/ml, or  1  x  10 L° reovirus type  I  particles/ml in carbonate-bicar- 
bonate buffer at pH 9.6, and incubated with 100 #1 of hybridoma superna- 
tant. Bound antibodies were revealed using peroxidase-coupled rabbit anti- 
body against mouse Ig, or against mouse IgA (Zymed Laboratories, South 
San Francisco, CA). 
Specific IgA-producing hybridomas were expanded and cloned two to 
three times by limiting dilution until stable antibody production was ob- 
tained. To produce antibody for characterization, hybridomas were adapted 
to grow in complete RPMI containing 1% Nutridoma-SP serum-free media 
supplement  (Boehringer  Mannheim Biochemicals,  Indianapolis,  IN)  in 
place of FBS. Antibody was stored at 4°C in PBS containing 0.5 % BSA and 
Table I. Immunization Procedures 
Immunization  Cells fused 
Protocol  day 0  day  14  day 21  day 24 
MMTV Immunization* 
Method A  i-PP  i.p.  i.p.  spleen, MLN,  PP 
Method B  i.I.  i.I.  i.p.  spleen, MLN,  PP 
Method C  i.l.  i.p.  i.p.  spleen, PP 
Reovirus Immunization 
Method A  i.l.  i.p.  i.p.  PP 
Method B  oral  oral  oral  PP 
* Two mice were immunized by each method shown. For MMTV immuniza- 
tion,  MMTV-infected ceils were  injected  on day  0,  followed  by  purified 
MMTV on days 14 and 21.  Purified reovirus  type l was used both for injec- 
tions (method A) and oral immunization (method B). i-PP, antigen injected into 
PP submucosa;  i.p.,  antigen  injected  intraperitoneally;  i.l.,  antigen  injected 
into the intestinal lumen. 
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pristane-primed BALB/c mice to produce antibody in ascitic fluid. 
Selected antibodies were labeled metabolically by incubating hybridoma 
cells  in  cysteine-deficient (2.5  #g/ml)  RPMI  (Selectamine  kit,  Gibco 
Laboratories) with 1%  Nutridoma and 250/~Ci [35S]cysteine for 18 h. 
Gel Electrophoresis and lmmunoblotting 
SDS-PAGE was performed according to Laemmli (14). MMTV-infected  GR 
cells were treated with lysis buffer (10 mM "Iris HCI,  1% NP40,  0.4% de- 
oxycholate, 60 mM EDTA, !mM PMSE 5/~g/ml each of pepstatin, leupep- 
tin, and antipain, pH 7.5) and centrifuged. Lysate supernatants and purified 
MMTV  were solubilized in  SDS  sample buffer containing 2-mercapto- 
ethanol. For endoglycosidase F treatment, 15/~g MMTV protein was solu- 
bilized in SDS sample buffer and 5 #l endoglycosidase F (Boehringer Mann- 
heim Biochemicals) in 100 mM phosphate buffer with 50 mM EDTA,  1% 
NP40,  1% 2-mercaptoethanol, 1 mM PMSE pH 6.5 was added. Samples 
were incubated overnight at 37°C, precipitated with TCA, and solubilized 
in SDS sample buffer.  After electropboresis and transfer to nitrocellulose 
(43),  immunoblots were blocked with 5%  nonfat dry milk and incubated 
with hybridoma culture medium followed by biotinylated rabbit anti-mouse 
Ig and streptavidin-peroxidase. 
Antibodies were denatured in SDS-sample buffer without reducing agent 
and heated to 100°C  for only 1 min to avoid breakdown of IgA polymers. 
IgA proteins were separated on 3-10% gradient gels and detected after dec- 
trophoretic transfer using peroxidase-coupled antibodies specific for mouse 
IgA (Zymed Laboratories). 
Immunoprecipitation 
Specificity of antireovirus IgA was determined by immunoprecipitation of 
35S-labeled reovirus proteins. L929 cells were grown in monolayers and in- 
fected with reovirus type 1 at a multiplicity of infection of 20. After 12 h, 
cells were incubated for 45  min in methionine-deficient MEM plus  100 
#Ci/ml [3SS]methionine,  chased for 30 min in cold methionine-containing 
medium, harvested into PBS, pelleted, and treated with lysis buffer contain- 
ing 0.5% deoxycholate and 0.1% NP40.  Aliquots of the lysate were mixed 
with hybridoma supernatant overnight at 4°C and immune complexes were 
precipitated with rabbit anti-mouse IgG/A/M.  Precipitated proteins were 
separated on 10% polyacrylamide geis and radiolabeled bands detected by 
fluorography. 
Radioimmunoassay 
To explore the specificity of IgA antibodies that immunoprecipitated both 
sigma 3 and mu Ic, the major outer capsid proteins common to reovirus 
types 1 and 3, a solid phase radioimmunoassay was performed using intact 
reovirus 1,  intact reovirus 3, and reovirus type 1 that had been protease- 
digested to yield intermediate subviral particles that lack sigma 3 but retain 
the major portion of mulc. Flexible 96-well plates were coated with 1.25 
t~g reovirus/well, blocked with 1% BSA in PBS, and exposed to hybridoma 
supernatants overnight at 4°C. After washing, wells were exposed to 125I- 
labeled rabbit anti-mouse IgG/A/M, separated, and counted. 
Liver Transport of  lgA 
Bile ducts of adult CD rats were cannulated with PE10 tubing (Clay-Adams, 
Parsippany, NJ; outside diameter 0.61 ram), and 2.5 to 7  x  l06 cpm of 35S- 
labeled IgA or IgG (,,o2/zg protein) were injected intravenously.  Bile was 
collected continuously from 15 min before to 3 h after antibody injection, 
and total radioactivity was determined by scintillation counting. For PAGE 
analysis of labeled protein, samples of stock labeled antibody and bile were 
diluted in SDS sample buffer and run without reduction on a 3-10 % gradient 
acrylamide gel. Dried gels were autoradiographed with x-ray film without 
fluorography. 
Autoradiography 
Monoclonal IgA was metabolically labeled with [3SS]cysteine as described 
above and diluted to 1.2  x  107 cpm/ml (*5/~g/ml antibody) in PBS con- 
raining 0.5% BSA. Mice were anesthetized with 2,2,2-tribromoethanol in 
tertiary-amyl alcohol and  50-100  #1  labeled antibody was injected into 
ligated intestinal loops, each of which contained a PP. After I h, loops were 
excised, quickly rinsed with PBS, and fixed in a  solution containing 2 % 
freshly depolymerized formaldehyde, 2.5% glutaraldehyde, 2 mM MgCI2, 
and 2 mM CaCI2 in 0.1 M sodium cacodylate buffer, pH 7.4.  Tissues were 
postfixed in 1% OsO4 in cacodylate buffer,  en bloc stained in 0.5% uranyl 
acetate, dehydrated with graded ethanols, and embedded in Epon-araidite. 
1-/zm sections were stained with iron hematoxylin, coated with Ilford K5 
emulsion diluted 1:1 with distilled water, and exposed at 4°C. After 3 wk, 
autoradiographs were developed (in D19;  Eastman Kodak Co., Rochester, 
NY) and photographed. 
Colloidal Gold  Probes and Binding  Assays 
Colloidal gold particles of 5 nm or 6-8 nm were produced and conjugated 
using standard methods (36) to mouse polyclonal lgG (Sigma Chemical 
Co., St. Louis, MO), rat polyclonal secretory IgA that contained secretory 
component (provided by Dr.  A. Plaut, Tufts University Medical School), 
BSA, or to mouse monoclonal IgA antibodies: either antireovirus antibodies 
RB2 and RB5, or MOPC 315, a myeloma IgA against TNP (Sigma Chemical 
Co.). Conjugates were stabilized with 0.5 % BSA, washed, and concentrated 
by centrifugation to a standard volume. Based on our experience with other 
gold conjugates, we assumed that no more than 25% of the protein used for 
conjugation remained bound to the gold after washing; the estimated final 
concentrations of gold-conjugated proteins were monoclonal IgAs RB2 and 
RB5, 180 #g/ml; MOPC 315 myeloma IgA, 300 #g/ml; rat slgA, 100/~g/ml; 
polyclonal IgG, 300/zg/ml; BSA, 2.4 mg/ml. Mice were anesthetized and 
a  standard volume (40-60 ~1) of each gold conjugate was injected into a 
ligated intestinal loop of uniform length containing a PP. After 1 h, loops 
were excised, quickly rinsed with PBS, and fixed and embedded as de- 
scribed above. Thin sections were stained with uranyl acetate and lead ci- 
trate and examined with an electron microscope (model  100CX;  JEOL 
USA, Peabody, MA). 
For examination of IgA-gold binding in the presence of excess unlabeled 
protein, a series of ligated loops were injected first with 30/zl of  excess com- 
petitor protein (either 50 mg/ml MOPC 315 IgA, 10 mg/ml lgG, or an equal 
concentration of BSA) and returned to the abdominal cavity. After 15 min, 
30/~1 of either MOPC 315 or RB5 IgA-gold conjugates were added to the 
loops. Based on estimated concentrations of protein in gold conjugates, this 
represented a  1,000-fold  excess of unlabeled competitor IgA protein and 
200-fold excess of unlabeled competitor IgG.  After 1 h, intestinal loops 
were processed for EM as described above. For each condition tested, all 
clearly visualized M cells in sections from 5 to 6 separate blocks of tissue 
were photographed and examined for IgA-gold binding. Numbers of M cells 
with and without surface-bound IgA-gold were tallied and differences com- 
pared by chi-square analysis for significance. In addition, we counted the 
number of IgA-gold particles bound per 10 ttm M cell luminal membrane 
as measured with a digitizing pad. A measuring magnifier was used to iden- 
tify gold particles that lay within 25 nm oftbe membrane, a distance consis- 
tent with direct membrane binding taking into account the dimensions of 
the polymeric IgA molecule (6). One factor analysis of variance was used 
to determine whether differences in surface density were significant. 
TNP-Ferritin Binding  Assays 
Horse spleen ferritin (Polysciences Inc., Warrington, PA) at a concentration 
of  0.022 mM in PBS was mixed with an equal volume of trinitrobenzenesul- 
fonic acid (Sigma Chemical Co.) at a concentration of 81.8 mM in PBS, and 
stirred for 1 h in the dark. Unreacted trinitrobenzenesulfonic acid was re- 
moved by passing the mixture over a Sephadex G25 column (PD-10; Phar- 
macia Fine Chemicals, Piscataway  N J). Conjugation of TNP to ferritin was 
confirmed by ELISA using anti-TNP monoclonal antibodies. To generate 
immune complexes, TNP-ferritin was mixed with MOPC-315 (anti-TNP) 
monoclonal IgA (final concentrations: 1 mg/ml TNP-ferritin and 5 mg/ml 
IgA) with 10 mg/ml BSA. As control, TNP-ferritin was mixed with RB2 
(antireovirus) monoclonal IgA under the same conditions. The mixtures 
were allowed to stand for 1 h before injection into intestinal loops. Visible 
precipitates did not form over this time, and EM revealed monodisperse fer- 
ritin particles with no aggregates. M cell binding assays, quantitation and 
statistics were done as described for colloidal gold probes. 
lmmunofluorescence 
Tissue was fixed in a solution of 10 mM NaIO4,  7.5 mM lysine, 3.7 mM 
Na2HPO4,  and 2% paraformaldehyde for 3 h at room temperature. Tissue 
was then treated for 45 min in PBS containing 50 mM NI-IaCI, infiltrated 
with 2.3 M sucrose, mounted on chucks coated with Tissue-Tek II (Lab-Tek 
Products, Naperville, IL), and frozen in liquid nitrogen-cooled Freon 22. 
Frozen sections (1/Lm) were cut on a cryomicrotome (model FC-4; Reicbert 
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hydes were blocked with 50 mM NI-hCI in PBS, and nonspecific protein 
binding was blocked with 0.2% gelatin in PBS. Sections were treated with 
primary antibody diluted in PBS/gelatin and with an appropriate secondary 
antibody, either rabbit anti-mouse IgG (preabsorbed with rat serum) con- 
jugated  to  rhodamine  (HyClone  Laboratories,  Logan,  Utah)  or  rabbit 
anti-rat IgG (preabsorbed with mouse serum) conjugated to fluorescein 
(HyCIone Laboratories). Sections were photographed with a light micro- 
scope (model PM3; Carl Zeiss, Inc., Thornwood, NY) using 400 ISO film 
(TMAX; Eastman Kodak Co., Rochester, NY) for both fluorescence and 
Nomarski optics. 
Results 
Production of  Anti-MMTV Monoclonal Antibodies 
Experiments using MMTV as immunogen were designed to 
determine whether cells obtained from PPs alone could be 
used to obtain hybridomas producing specific antivirus IgA. 
Mice were immunized by three different immunization pro- 
tocols, one involving injection of antigen directly in PP sub- 
mucosa and the others involving one or two injections into 
the intestinal lumen (Table I). Cells from PP mucosa, mesen- 
teric lymph nodes (MLN), and spleen were each fused sepa- 
rately with myeloma cells. 
All  three  immunization methods  and  all  three  tissues 
yielded hybridomas that produced anti-MMTV antibody. Of 
the eight hybridomas that produced specific IgA antibodies, 
seven  were  derived  from PP  cells  (Table  II).  Two  anti- 
MMTV  IgA-producing  hybridomas  were  obtained  from 
mice immunized by method A (intra-PP and i.p. injections), 
but neither of these proved stable.  Six anti-MMTV IgA hy- 
bridomas were derived from PP cell fusions after i.l. injec- 
tions (methods B and C); two (designated MB2 and MB3) 
remained stable during expansion and were cloned twice be- 
fore further characterization. Although the number of stable 
MMTV specific IgA hybridomas obtained in this study was 
too small to determine which immunization protocol was 
most effective, the results suggest that injection directly into 
PP submucosa had no advantage over i.1. immunization, and 
that IgA-producing hybridomas could be produced by fusing 
PP cells. 
Table II. Production of  Anti-MMTV Hybridomas 
Anti-MMTV 
positive wells~  t 
Immunization  Cell source  Wells screened  Non-IgA  IgA§ 
Method A  PP  152  1  1 
(i-PP/i.p./i.p.)*  MLN  120  3  0 
spleen  192  15  1 
Method B  PP  124  0  5 
(i.1./i.l./i.p.)  MLN  136  1  0 
spleen  192  7  0 
Method C  PP  176  1  1 
(i.l./i.p./i.p.)  spleen  192  13  0 
* i-PP,  injections into PP submucosa;  i.p.,  intraperitoneal  injection;  i.l.,  in- 
jection into lumen of intestine.  For details,  see Table  I and Methods. 
~: Number of wells producing anti-MMTV antibody of non-IgA (IgG and IgM) 
and IgA  isotypes.  Specific  antibody  production  was determined by ELISA 
assay. 
§ Of the IgA-producing  hybridomas identified  in early screening, only two 
continued  to produce  antibody after expansion. 
Table IlL Production of  Antireovirus Hybridomas 
Anti-MMTV 
positive wells;  t 
Immunization  Cell source  Wells screened  Non-IgA  lgA§ 
Method A  PP  288  15  8 
(i.1./i.l./i.p.)* 
Method B  PP  337  9  4 
(oral/oral/oral) 
* i.l.,  injection into lumen of intestine;  i.p.,  intraperitoneal  injection.  For de- 
tails,  see Table I and Methods. 
Number of wells producing antireovirus antibody of non-lgA (IgG and IgM) 
and  IgA  isotypes.  Specific  antibody  production  was determined by  EL1SA 
assay. 
§ Of the lgA-producing hybridomas identified in early screening, only 10 con- 
tinued to produce antibody  after expansion. 
Production of  Antireovirus Monoclonal Antibodies 
To obtain specific antireovirus type 1 IgA hybridomas, PP 
cells alone were used for fusion after two immunization pro- 
tocols (Table I). One protocol consisted of two i.1. injections 
followed by an i.p. boost, and the other consisted of three 
oral doses of virus with no injections. One-third of the anti- 
reovirus monoclonal antibodies generated by both protocols 
were of the IgA isotype (Table III). From 12 wells initially 
positive for antireovirus IgA, 10 stable hybridomas were ob- 
tained, 6 from mice immunized intraluminally, and 4 from 
mice immunized orally. These hybridomas were expanded, 
cloned twice or more until stable, and designated RB1  to 
RB10. 
Specificity of  Antivirus Monoclonal IgA Antibodies 
The  specificity of anti-MMTV  IgA antibodies  MB2  and 
MB3 was examined by immunohlot analysis. MB3 did not 
recognize its antigen on immunoblots, but MB2 bound to a 
52-kD band when tested against purified MMTV particles 
(Fig. 1 A). The band co-migrated with gp52, the major enve- 
lope glycoprotein of MMTV. MB2 also recognized its anti- 
gen after  MMTV  proteins  were  deglycosylated with en- 
doglycosidase E  Since the MMTV envelope glycoprotein 
gp52 does not contain O-linked carbohydrates (3), this indi- 
cates that MB2 is not directed against a carbohydrate epitope. 
To provide further evidence that MB2 binds to gp52,  we 
tested it on immunoblots of lysates from control GR cells, 
which produce low levels  of MMTV, and dexamethasone- 
Table IV. Binding of  Monoclonal IgA Antibodies to 
Complete Reovirus Particles (Serotypes I and 3) and 
Intermediate Subviral Particles 
cpm bound per well* 
Reovims  Reovirus 
Monoclonal  IgA antibody  type 3  type 1  type 1 ISVP;  t 
RB2  30,930  28,995  652 
RB3  19,990  16,290  466 
RB8  8,374  11,474  10,806 
* Binding  of antibody  was  determined by  solid-phase  radioimmunoassay. 
Wells were coated with virus particles  and treated with the indicated  mono- 
clonal antibodies  followed by ~2sI-iabeled  anti-mouse Ig antibody. 
Reovirus  type 1 intermediate  subviral particles  (ISVP). 
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Immunoblot  analysis showing that  MB2  recognized  the  major 
MMTV  surface glycoprotein gp52.  Proteins of purified MMTV 
and MMTV-infected GR cells were electrophoresed on a 10-15% 
SDS polyacrylamide gel and transferred to nitrocellulose. Lanes 
1-4 show Ponceau red staining of proteins. Lanes 5-8 show identi- 
cal lanes immunostained with antibody MB2. Lanes I and 5 show 
proteins of purified MMTV particles. Lanes 2 and 6 show endo- 
glycosidase F-treated MMTV proteins. Lanes 3 and 7show extracts 
of control GR cells. Lanes 4 and 8 show extracts of GR cells treated 
with dexamethasone to stimulate MMTV production. Arrowheads 
(right) indicate  major MMTV protein bands: gp52 and gp52 after en- 
doglycosidase F  treatment,  and p28. Molecular  mass standards 
(left) are in kilodaltons. (B) Immunoprecipitation of 35S-labeled 
viral proteins from lysates of reovirus-infected cells. Immunopre- 
cipitates were run on a 10% polyacrylamide gel and radiolabeled 
bands detected by fluorography. Lanes 1-5 show precipitation by 
monoclonal IgAs RB2, RB3, RB4, RB5, and RB8. Lane 6 shows 
precipitation by monoclonal IgG antibody 5C6 against the sigma 1 
protein of reovirus type I. Lanes 7and 8 show precipitation by an- 
tisera against reovirus type 1 (lane 7) and type 3 (lane 8). There 
was decreased precipitation of type 1 sigma 1 by anti-type 3 anti- 
bodies. Major reovirus proteins are indicated at right. Molecular 
masses of viral proteins mu lc and sigma 3 are indicated at left. 
treated GR cells, which produce high levels of  MMTV. Bind- 
ing to the 52-kD band was greatly enhanced with dexametha- 
sone-treated cells, suggesting that the band represented an 
MMTV protein. 
All of the antireovirus IgA antibodies that recognized reo- 
virus type 1 in ELISA assays also recognized reovirus type 
3;  this  was  confirmed by solid  phase  radioimmunoassay. 
Types 1 and 3 are defined by the nature of the serological re- 
sponse to the sigma 1 outer capsid protein, the viral hemag- 
glutinin  known to  be a  potent systemic immunogen (35). 
These results therefore suggest that none of the mucosally 
derived IgA antibodies recognized sigma 1. Since none of the 
antireovirus IgA antibodies detected viral proteins on West- 
ern blots,  specificity was determined by immunoprecipita- 
tion  from lysates  of 35S-labeled  reovirus-infected cells  as 
shown in Fig.  1 B.  Three antibodies, RB2,  RB3,  and RB8 
(all obtained from intraluminally immunized mice) immuno- 
precipitated proteins that co-migrated on gels with sigma 3 
(34 kD) and mu lc (72 kD), two major components of the 
reovirus outer capsid that are closely associated in intact vi- 
rus and in infected cell lysates (35). We therefore wished to 
determine if these antibodies recognized sigma 3 or mu lc. 
Sigma 3 can be removed from the virus particle by protease 
treatment,  leaving intermediate subviral particles in which 
the major portion of mu lc is present as a cleaved product. 
When intermediate subviral particles were used in radioim- 
munoassay, binding of two antibodies (RB2 and RB3) was 
markedly reduced (Table IV), suggesting that these antibod- 
ies reacted with sigma 3, or possibly with the portion of mu 
lc that had been removed. 
Polymeric State of  lgA Antibodies Produced by 
PP-derived Hybridomas In Vitro 
To determine whether the monoclonal IgA antibodies were 
produced as polymers, concentrated culture media from IgA- 
producing hybridomas RB1  through RB10 were run on a 
nonreducing gel,  transferred to nitrocellulose, and reacted 
with peroxidase-conjugated antibody specific for mouse IgA 
(Fig. 2). Monomeric and polymeric IgA bands showed lower 
apparent molecular masses than expected for complete mouse 
IgA, presumably because of the absence of covalent bonds 
between IgA heavy and light chains in BALB/c mice (45) that 
causes dissociation of light chains in SDS sample buffer. The 
apparent molecular masses of the IgA bands were neverthe- 
less consistent with their being IgA monomers, dimers, and 
higher polymers. In all cases, the majority of IgA was pres- 
ent in polymeric form. 
Transfer of lgA from Blood to Bile 
Three monoclonal IgA antibodies (RB2, RB3, and IL1M) and 
one monoclonal IgG (directed against Vibrio cholerae) were 
metabolically labeled with [35S]cysteine and injected intrave- 
nously into rats in which the bile duct had been cannulated. 
Rat  liver  polymeric  immunoglobulin  receptors  can  bind 
mouse IgA and in rats, IgA is transported from blood to bile 
much more efficiently than in mice (12). Fig.  3 shows that 
34, 45, and 58 % of the radiolabeled IgA activity was recov- 
ered in the bile over 3 h, suggesting that the monoclonal IgA 
antibodies bound to liver polymeric immunoglobulin recep- 
tors and were transported into the bile. In contrast, only 3% 
of the injected IgG activity was recovered in the bile. When 
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ing in vitro production of monomeric and polymeric IgA. Concen- 
trated serum-free medium from antireovirus IgA-producing hybrid- 
omas RB1-RB10, and one IgG-producing hybridoma,  were run on 
a nonreducing 3-10% polyacrylamide gel, transferred to nitrocellu- 
lose,  and  immunostained  with peroxidase-coupled  antibody  spe- 
cific for mouse IgA. Each IgA was produced  in monomeric (lane 
1,  single arrowhead),  dimeric  (lane  1,  double arrowhead),  and 
higher polymeric forms. The lack of  reaction in the IgG control lane 
shows that immunostaining was specific for IgA. Positions of mo- 
lecular mass standards in kilodaltons are shown. 
Figure 4.  Paired samples of stock 35S-labeled IgA (RB2, RB3, and 
RB4) that were injected i.v. into rats, and bile from the rat in which 
it was injected,  were run without reduction on a 3-10% gradient 
polyacrylamide gel and autoradiographed.  Monomeric (single ar- 
rowheads) and dimeric (double arrowheads) IgA are identified in 
the first two lanes. Higher polymer bands are seen above the dimer 
bands. The shift in mobility of polymeric IgA in the bile samples 
suggests that it was associated with secretory component. Positions 
of molecular mass standards in kilodaltons are shown. 
labeled IgA antibodies were run on nonreducing acrylamide 
gels and autoradiographed,  radioactive bands were seen at 
positions corresponding to monomeric and polymeric IgA 
(Fig. 4).  Bile from animals that had been injected with la- 
beled IgA showed radioactive bands at positions correspond- 
ing to polymeric IgA, but with apparent molecular masses 
,x,60 kD higher than those of stock labeled IgA, an increase 
consistent with addition of secretory component. 
IgA Binding and Transport 
To test whether IgA interacts with the intestinal epithelium, 
we used light microscope autoradiography and EM of PP tis- 
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Figure 3. Transport of monoclonal IgA from blood to bile. Three 
monoclonal IgAs and one monoclonal IgG were metabolically la- 
beled with [3~S]cysteine and injected intravenously into adult rats. 
Over a 3-h period, 34-58%  of injected [3SS]cysteine was recovered 
in bile. In contrast, very small amounts of [35S]cysteine were recov- 
ered after labeled IgG injection. 
sue treated with radiolabeled IgA or IgA-colloidal gold.  M 
cells were identified in the lymphoid FAE by the presence 
of intraepithelial lymphocytes. By EM, M cells were recog- 
nized by their short, irregular microvilli and the invaginated 
basal membrane that  forms a  pocket containing  lymphoid 
cells (Fig. 5). Light microscope autoradiography of PP FAE 
after  1 h  luminal  exposure to "S-labeled antireovirus IgA 
showed clusters of grains associated with M  cells (Fig. 6). 
No label was detected in epithelial cells of adjacent villi. EM 
of mouse PP tissue exposed to colloidal gold conjugated to 
antireovirus IgA antibodies (RB2 or RB5) or to anti-TNP IgA 
(MOPC 315) revealed selective association of IgA-gold parti- 
cles with M cell surfaces (Fig. 7). IgA-gold particles adhered 
to  M  cell  luminal  membranes  both  individually  and  as 
clusters. Frequently, IgA-gold was seen in M cell intracellu- 
lar vesicles (Fig. 8, A and B) and within the intraepithelial 
pocket (Fig. 8 C). In EM sections from two experiments, 42 
and 48% of M cells with surface-bound IgA-gold also showed 
probe in endocytic vesicles and/or the intraepithelial pocket. 
Small amounts of IgA-gold bound to non-M columnar cells 
of the FAE but not to the absorptive epithelium of adjacent 
villi. In contrast, BSA-gold did not bind to M cells and was 
rarely internalized.  Identical binding and transport patterns 
were observed in rat and rabbit PPs exposed to mouse IgA- 
gold and in mouse PPs exposed to rat polyclonal secretory 
IgA-gold (not shown). 
Binding of IgA-gold in the presence of 1,000-fold  excess 
unlabeled IgA, or comparable amounts of excess BSA, was 
examined to test the  specificity of binding.  Inhibition was 
measured by scoring the percentage of M cells with IgA-gold 
bound to their surfaces (Fig. 9 A), and by counting the num- 
ber of IgA-gold particles per 10/~m of membrane (Fig. 9 B). 
By both criteria,  unlabeled anti-TNP IgA significantly  in- 
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columnar  cells  (CC)  of mouse 
lymphoid  FAE. The typical  M 
cell has short, irregular microvilli 
and a basolateral pocket (P) into 
which  lymphoid cells  (here  re- 
sembling plasma cells) and mac- 
rophages migrate. Luminal anti- 
gens are endocytosed, transported 
across the  thin bridge  of apical 
cytoplasm (bracket), and  deliv- 
ered  to  the  basolateral  pocket. 
Bar,  1 /zm. 
hibited binding of both anti-TNP IgA-gold and antireovirus 
IgA-gold conjugates. 
To determine whether binding was confined to antibodies 
of the IgA class, we examined binding of polymeric mouse 
IgG conjugated to colloidal gold.  IgG-gold, like IgA-gold, 
bound to M cells but not to villus absorptive cells, and IgG- 
gold was transported to the M cell pocket. IgA-gold binding 
was reduced by 52 % in the presence of excess IgG (as com- 
pared to binding in the presence of an equal amount of excess 
BSA).  Thus, IgA and IgG share M  cell binding sites. 
Binding of  lgA-Antigen Complexes 
To determine the effect of specific IgA on binding and trans- 
port of antigen by M cells, we used the hapten TNP (rendered 
visible by conjugation to ferritin) and specific monoclonal 
anti-TNP IgA.  This system was used because TNP-ferritin 
binding to M cells is readily assessed quantitatively in EM 
sections; quantitation of virus binding and transport will re- 
quire extensive studies that are beyond the scope of this re- 
port.  Mouse PP were exposed to TNP-ferritin mixed with 
fivefold excess of either anti-TNP IgA or as control, anti- 
reovirus IgA.  Adherence of TNP ferritin to M  cell apical 
membranes was enhanced about 10-fold by the presence of 
specific anti-TNP IgA (Fig.  10). 
Absence of Previously Described lmmunoglobulin 
Receptors on M  Cells 
Frozen 1/~m sections of PP FAE were examined by immu- 
nofluorescence for the presence of immunoglobulin recep- 
tors previously identified on epithelial cells or macrophages. 
Fig.  11, A-D, shows paired fluorescence and Nomarski opti- 
cal images of rabbit tissue treated with monoclonal antibody 
166 against the cytoplasmic tail of the polymeric immuno- 
globulin receptor (39).  The receptor was present on villus 
absorptive cells, hut was not observed on epithelial cells of 
Figure 6. Association oflgA with M cells (M) of  mouse FAE shown 
by light microscopic autoradiography. PP mucosa was exposed for 
1  h  to 35S-labeled monoclonal antireovirus IgA. Autoradiography 
shows label associated with M cells but not with villus epithelium 
(V). Arrow indicates M cell-associated cluster of silver grains. Bar, 
10 gm, 
Weltzin et al. Binding of Monoclonal lgA to Intestinal M Cells  1679 Figure 7. Electron micrograph of  the apical surface of  an M cell from a mouse PP after 1 h luminal exposure to mouse monoclonal antireovi- 
rus IgA conjugated to 6-8 nm colloidal gold. IgA-gold adhered closely to luminal membranes of M cells (M) but not to villus absorptive 
cells. Bar, 0.2/~m. 
the FAE, including M  cells.  Fab fragments of monoclonal 
antibody 2.4G2 against the high avidity macrophage Fc re- 
ceptor (19) bound to subepithelial macrophages in sections 
of mouse PP tissue,  but did not bind to cells of the FAE 
(Fig.  11, E-H). Monoclonal antibody MC39 against epithe- 
lial Fc receptors of neonatal rat jejunum (32) also failed to 
bind to M cells or other epithelial cells of the adult rat FAE 
(Fig.  11, I-L). 
Discussion 
Role of M Cells in Mucosal Immunity 
Transepithelial transport by M cells appears to be an impor- 
tant event in generation of secretory immune responses to 
luminal antigens (4,  25,  37).  These specialized cells, con- 
fined to lymphoid FAEs of digestive and respiratory mucosal 
surfaces, are invaginated basally to form an intraepithelial 
pocket into which lymphocytes and macrophages migrate (4, 
7,  25).  Rapid transepithelial transport of luminal antigens 
into this pocket is believed to allow local antigen sampling 
by cells of the mucosal immune system, but it is not known 
whether M cells play a more specialized role in modulating 
the wide variations observed in mucosal immune responses 
to diverse luminal antigens (17, 37). M cells are devoid of Ia 
antigen (17), and there is no evidence to date that they are 
capable of antigen presentation, but they could modulate im- 
mune responses by determining the dose, concentration, or 
form of antigen delivered. For example, we previously dem- 
onstrated that luminal lectins that adhere to M cell surfaces 
were transported across the epithelium at least 50 times more 
efliciently  than BSA, a protein that does not adhere (23). Par- 
ticulate antigens and microorganisms that can adhere to and 
colonize epithelial surfaces are generally more effective in 
eliciting secretory immunity than those that do not adhere 
(17, 28,  30).  If we are to eventually predict or manipulate 
secretory immune  responses,  it  is  important  to  precisely 
correlate M cell transport of specific luminal antigens with 
the mucosal immune response, and also to define the influ- 
ence of secreted antibodies on  subsequent  transepithelial 
transport of antigen by M  cells. 
Role of  M Cells in Transport of Viruses 
Reovirus type 1 adheres specifically to the luminal surfaces 
of M  cells of PP (48) and uses the M  cell transepithelial 
transport system to invade and colonize the mucosa before 
spreading to distant sites (35). The function of several reovi- 
ms outer capsid proteins are established; for example, sigma 
1 mediates the tissue specificity of systemic spread (11). It is 
The Journal of Cell Biology, Volume  108, 1989  1680 Figure 8. Electron micrographs of M cells from mouse PPs after 1 h luminal exposure to mouse monoclonal IgA conjugated to 5 nm or 
6-8 nm colloidal gold. Bars, 0.1/~m. (A) Anti-TNP IgA-gold (arrows) on the M cell surface and within a vesicle of the type previously 
shown to transport  macromolecules  to the basolateral pocket.  (B) IgA-gold in an M cell (M) vesicle (arrow) close to a portion  of the 
basolateral pocket that contains a lymphocyte (L). The extracellular space is indicated by an arrowhead. (C) IgA-gold (arrow)  in the extracel- 
lular space of the M cell pocket. 
not known, however, which viral protein mediates initial at- 
tachment to M cell surfaces (47). In any case, adherence of 
reovirus to M  cells enhances manifold the efficiency with 
which reovirus invades the mucosa via the M cell route, and 
may also facilitate development of a  mucosal immune re- 
sponse.  Enteric administration of reovirus has been shown 
to elicit a mucosal immune response as reflected by intestinal 
secretion  of antivirus  IgA  antibodies  (34),  generation  of 
memory B ceils committed to IgA production, and long-lived 
virus-specific cytotoxic T cells in PP (15).  MMTV, a retrovi- 
rus that is shed into the milk of infected mothers and infects 
offspring during the suckling period, gains access to host tis- 
sues by transepithelial transport across the intestinal epithe- 
lial barrier (21).  The exact sites of MMTV invasion in the 
gastrointestinal  tract  are  not  established  (10).  Whether 
MMTV selectively adheres to M cells to gain access to the 
host is currently being tested. 
Our initial plan was to use monoclonal antibodies of known 
specificities in attempts to block virus attachment to intesti- 
nal epithelial cells and thus identify the viral surface proteins 
that mediate attachment. IgG antibodies would be unsuitable 
for these studies because they are degraded in the intestinal 
lumen whereas  secretory IgA, because of the presence of 
secretory component,  is more stable (44).  Therefore,  our 
first goal was to generate hybridomas that produce polymeric 
antivirus IgA antibodies and to test these antibodies for their 
binding specificities and ability to associate with secretory 
component. 
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Figure 9. M cell binding of anti-TNP (MOPC 315) and antireovirus 
(RB5) IgA-colloidal gold conjugates in the presence of approxi- 
mately 1000-fold excess of unlabeled MOPC 315 IgA, or a com- 
parable excess of BSA. (,4) The percentage of M cells with surface- 
bound IgA-gold. Chi square analysis of  this data showed that excess 
unlabeled MOPC 315 IgA caused a significant decrease in binding 
of both MOPC 315 (p =  0.002) and RB5 (p  =  0.004). (B) The 
mean number of surface-bound IgA-gold particles per 10 #m of M 
cell luminal membrane. Vertical bars indicate the SEM. Analysis 
of  variance confirmed that excess unlabeled IgA caused a significant 
decrease  in binding of both  MOPC 315  (p  =  0.010) and  RB5 
(p  =  0.007). 
PP Cells  from Orally Immunized Mice as a Source of 
Polymeric IgA Antibodies 
Our results establish that PP cells are effective in generating 
IgA-secreting  hybridomas  when  directly  fused  with  my- 
eloma cells. IgA-producing hybridomas have been generated 
previously using  spleen cells  from mucosally immunized 
animals (8,  18),  but the technique is not always  successful 
(9).  Cells from MLN and thoracic duct lymph (31, 41) or 
mixed cells from MLN and PPs (13) have been used success- 
fully, and it was suggested that PP lymphocytes alone may 
be  effective in  generating  IgA-secreting hybridomas  (41). 
Our results support this hypothesis and suggest that PP cells 
3- 
~.~  I 
0 ~ 
with  with 
control lgA  anti-TNP IgA 
Figure 10. Binding of TNP-ferritin to M cells in the presence of con- 
trol (antireovirus) IgA (RB2) or anti-TNP IgA (MOPC 315). Bars 
show the mean number of surface-bound ferritin particles per 10 
#m of M cell luminal membrane. Vertical bars indicate the SEM. 
Analysis of variance showed that binding in the presence of anti- 
TNP IgA was significantly greater than binding with control IgA 
(p  =  0.004). 
may  be  better  than  either  spleen  or  MLN  cells  for this 
purpose. 
Binding  specificities were determined for several of the 
resulting antivirus monoclonal IgA antibodies,  identifying 
viral proteins that are able  to elicit mucosal  immune  re- 
sponses.  For  reovirus,  the  outer  capsid  protein  sigma  3 
proved to be immunogenic after i.l. (but not oral) administra- 
tion of virus.  For MMTV, the major surface glycoprotein 
gp52 was identified as a mucosal immunogen. Identification 
of other potential immunogens will require further fusions. 
The hybridomas described in this paper produced IgA pri- 
marily inr the expected polymeric forms, the majority being 
dimeric. We demonstrated that antireovirus monoclonal IgA 
antibodies were efficiently transported from blood to bile, 
confirming their ability to interact with liver polymeric im- 
munoglobulin receptors. SDS-PAGE of bile proteins followed 
by autoradiography showed that the polymeric antibody mol- 
ecules were transported intact, and that secretory component 
was added on passage through the liver. Having confirmed 
that these monoclonal, polymeric IgA antibodies were anal- 
ogous to IgA produced in vivo, we proceeded to apply them 
to mucosal surfaces. 
M Cells Express lmmunoglobulin Binding Sites 
Mouse monoclonal IgA antibodies adhered selectively to M 
cell luminal membranes in the intestinal epithelia of adult 
mice, rats, and rabbits, and were transported transepitheli- 
ally, regardless of their antigen specificities. IgG also bound 
to M cell surfaces and inhibited IgA binding. Together, these 
results suggest that a common immunoglobulin domain me- 
diates adherence to M cells and that the cell surface binding 
site is not species specific. Since slgA is the principal immu- 
noglobulin present in the adult intestinal lumen (42), Ig bind- 
ing sites on M cells in vivo would presumably interact pri- 
marily with slgA. Immunocytochemical studies of  developing 
PPs in suckling rabbits showed that endogenous IgA from in- 
gested milk accumulates on M cell surfaces in FAE (33). We 
have now demonstrated that purified polyclonal slgA binds 
The Journal  of Cell Biology, Volume 108, 1989  1682 Figure 11. Immunofluorescent staining and matched  Nomarski images of 1-#m sections of intestinal mucosa treated  with monoclonal anti- 
bodies against immunoglobulin receptors.  (A-D) Rabbit mucosa treated with mouse monocional antibody 166 against the polymeric immu- 
noglobulin receptor (39).  (A and B) Villus epithelium  showing presence of receptor in absorptive epithelial  cells.  (C and D) FAE of PP 
showing absence of receptor on all FAE epithelial  cells,  including  M cells (arrow). (E-H) Mouse PP mucosa treated  with rat monoclonal 
antibody 2.4G2 against  macrophage Fc receptor (19).  (E and F) Subepithelial  area showing receptor-positive  macrophages.  (G and H) 
FAE showing absence of receptor on M ceils  (arrow) or other FAE epithelial  cells.  (l-L) Rat mucosa treated  with monoclonal antibody 
MC39 against  the neonatal  rat jejunum immunoglobulin receptor (32).  (I and J) Neonatal  rat jejunum showing  intracellular  and brush 
border staining  of absorptive epithelial  cells.  (K and L) FAE of adult rat PP showing absence of reactivity  with M cells (arrow) or other 
epithelial  cells.  Bar,  10/,tm. 
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complexed with secretory component, it is clear that IgA can 
bind selectively to M  cells whether or not secretory com- 
ponent is present.  There is indirect evidence that M  cells 
have unique apical surface components: certain microorgan- 
isms including reovirus (47, 48) and Escherichia coli strain 
RDEC-1 (37) bind selectively to this cell type. The molecular 
basis for these interactions is unknown. Proteins previously 
shown to bind to M cell membranes (certain lectins and cat- 
ionized ferritin) are nonselective in that they bind to all intes- 
tinal cell types (23).  Thus,  immunoglobulins are the only 
macromolecules identified to date that bind selectively to M 
cells in the adult intestinal epithelium. We have further shown 
that the presence of specific IgA in the intestinal lumen en- 
hances binding of antigen to these cells. Additional studies 
are required to determine whether IgA also enhances binding 
and transport of enteric viruses. 
Our previous studies  showed that adherence to M  cells 
greatly increases the efficiency of transepithelial transport 
(23). Selective transepithelial transport of IgA-antigen com- 
plexes in vivo would serve to deliver these complexes to in- 
traepithelial  and  subepithelial  macrophages  and  lympho- 
cytes for subsequent antigen processing and presentation. It 
is thus important to determine whether M cells express im- 
munoglobulin receptors similar or identical to those previ- 
ously identified on intestinal epithelial cells or macrophages. 
Using  specific antibodies applied to appropriate intestinal 
tissues, we confirmed that M cells do not express the poly- 
meric immunoglobulin receptor of enterocytes that mediates 
delivery of slgA into the intestinal lumen (38,  39). Indeed, 
this receptor has been shown to be absent from the entire 
FAE (26).  Nor do M  cells express macrophage-type high 
avidity Fc receptors: subepithelial macrophages of PPs were 
labeled  by  Fab  fragments  of specific antimacrophage  Fc 
receptor antibodies (19), but epithelial cells were not. Anti- 
bodies specific for the epithelial Fc receptors that mediate 
transepithelial transport of maternal milk IgG in suckling rat 
jejunum (32) also failed to recognize any component of M cell 
membranes. The nature of the M cell membrane components 
responsible for immunoglobulin adherence is currently un- 
der investigation in our laboratories. 
Conclusion 
Our results suggest that luminal antigens and microorgan- 
isms complexed with slgA could be "targeted" to M cell sur- 
faces, and selectively transported to underlying macrophages 
and lymphoid cells (Fig.  12).  Considerable evidence indi- 
cates that slgA effectively reduces accumulation of antigens 
and colonization of microorganisms on mucosal surfaces (1, 
2, 44, 46). Nevertheless, it is likely that small amounts of 
antigens or pathogens gain access to the vast epithelial sur- 
face of the intestine despite the presence of specific slgA. 
Efficient M cell binding and transport of these IgA-antigen 
complexes could serve to enhance or sustain the mucosal im- 
mune response once it has been initiated. This may explain 
why repeated oral administration of antigens has been shown 
to result in a persistent secretory immune response (40). It 
also suggests that the efficacy of oral immunization strategies 
might in some cases be enhanced by administration of im- 
munogens  in  the form of IgA-antigen complexes.  On  the 
other hand, IgA-mediated M cell transport of viruses could 
also promote invasion and infection. 
.t 
1~  2  Figure 12. Model of selective 
binding and transport of anti- 
gen-IgA complexes  by M cells. 
(1)  Most  antigens or  virus 
particles  that  are  complexed 
with slgA in the lumen would 
be cross-linked, eliminale.d  by 
peristalsis, and prevented  from 
binding  to  absorptive  cell 
surfaces. (2) Virus-IgA com- 
plexes that contact the mucosal 
surface would bind to M cell 
receptors,  and (3)  would be 
transported  transepithelially, 
into  the  M  cell  pocket.  (4) 
Virus-IgA complexes could then be phagocytosed by macrophages 
(Mac) and sampled by lymphocytes (L), or have access to sub- 
epithelial lymphoid tissue. This could lead to presentation of viral 
antigens, or to infection of macrophages and lymphoid cells. 
The monoclonal antivirus IgA antibodies described in this 
study, with and without secretory component, can now be 
applied in vivo and in vitro to establish more clearly the role 
of IgA in adherence and transepithelial transport of enteric 
viruses and other antigens in FAE. Application of these tools 
to murine viral systems may provide new insight into the pos- 
sible interactions of human enteric viruses with the intestinal 
epithelium and with the mucosal immune system. 
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